SCHEMBL55092

SCHEMBL55092

CS(=O)(=O)c1ccc(N)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.62
LMNA P02545 1/20 0.62
MPO P05164 1/20 0.62
CYP3A4 P08684 1/20 0.62
CYP2C9 P11712 1/20 0.62
HTR6 P50406 1/20 0.62
CA1 P00915 4/20 0.59
CA2 P00918 4/20 0.59
CA12 O43570 3/20 0.59
CA9 Q16790 3/20 0.59
CA14 Q9ULX7 2/20 0.59
TDP1 Q9NUW8 2/20 0.59
USP2 O75604 1/20 0.59
CA4 P22748 1/20 0.59
CA6 P23280 1/20 0.59
CA5A P35218 1/20 0.59
CA7 P43166 1/20 0.59
CA13 Q8N1Q1 1/20 0.59
AGO2 Q9UKV8 1/20 0.59
CA5B Q9Y2D0 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL560710 0.97 GAA (0.60) TSHRLMNAMPOCYP3A4CYP2C9
SCHEMBL5316043 0.93 CA12 (0.64) TSHRLMNAMPOCYP3A4CYP2C9
SCHEMBL7142643 0.87 GFER (0.58) TSHRLMNAMPOCYP3A4CYP2C9
SCHEMBL178009 0.87 ALDH1A1 (0.58) TSHRLMNAMPOCYP3A4CYP2C9
SCHEMBL2376239 0.85 ENPP2 (0.72) ENPP2PTGS2
SCHEMBL8487915 0.83 PTGS2 (0.75) PTGS2
SCHEMBL22495385 0.82 MAPT (0.58) LMNATDP1USP2ALDH1A1GAA
SCHEMBL3929345 0.79 TSHR (0.56) TSHRLMNAMPOCYP3A4CYP2C9
SCHEMBL6096079 0.78 CA2 (0.64) TSHRCA1CA2CA12CA9
SCHEMBL10484185 0.77 AKR1C3 (0.49) TSHRLMNAMPOCYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1840 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026097199-A1 SINTERABLE BONDING MATERIAL AND SEMICONDUCTOR DEVICE USING THE SAME HENKEL AG & CO. KGAA (DE) 2026-05-15 WO claimed
CN-120192259-A High-yield synthesis method of idexalone 安徽峆一药业股份有限公司 2025-06-24 CN claimed
CN-119613279-A N-substituted benzene ring bioisostere and preparation method thereof 上海交通大学 2025-03-14 CN claimed
CN-115260098-B Application of ABCB5 inhibitor in preparation of multi-drug-resistant rheumatoid arthritis treatment drug 澳门科技大学 2024-06-04 CN claimed
CN-117682975-A Preparation method of idexalone 重庆东得医药科技有限公司 2024-03-12 CN claimed
CN-117586166-A Compound for preparing Ai Shali ketone and preparation method thereof 重庆东得医药科技有限公司 2024-02-23 CN claimed
CN-116535280-A Synthesis method of alkynyl thioether compound 江南大学 2023-08-04 CN claimed
WO-2023035571-A1 SYNTHESIS METHOD FOR ESAXERENONE AND INTERMEDIATE THEREOF 上海鼎雅药物化学科技有限公司 2023-03-16 WO claimed
CN-115784961-A Synthesis method of oxacillin and intermediate thereof 上海鼎雅药物化学科技有限公司 2023-03-14 CN claimed
CN-115260098-A Application of ABCB5 inhibitor in preparation of multi-drug-resistance rheumatoid arthritis treatment drug 澳门科技大学 2022-11-01 CN claimed
US-20050080095-A1 administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I ABBVIE INC. 2005-04-14 US claimed
WO-2005007642-A2 NOVEL AZAHETEROCYCLIC AMIDES USEFUL FOR TREATING PAIN ABBOTT LABORATORIES (US) 2005-01-27 WO claimed
US-6696567-B2 INHIBITION OF PROTEIN KINASES OR JANUS KINASE 3; TREATING OR PREVENTING ORGAN TRANSPLANT REJECTION, XENO TRANSPLATION, LUPUS, MULTIPLE SCLEROSIS, RHEUMATOID ARTHRITIS, PSORIASIS, TYPE I DIABETES OR VARIOUS DISEASE COMPLICATIONS PFIZER INC. 2004-02-24 US claimed
US-20030220353-A1 Pyrrolo[2,3-d]pyrimidine compounds PFIZER INC. 2003-11-27 US claimed
EP-1294724-A1 PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS Pfizer Products Inc. (US) 2003-03-26 EP claimed
US-20020068746-A1 Pyrrolo[2,3-d]pyrimidine compounds PFIZER INC. 2002-06-06 US claimed
WO-2002000661-A1 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS PFIZER PRODUCTS INC. (US) 2002-01-03 WO claimed
EP-0073454-B1 6-ALPHA-METHOXY-PENICILLINS, THEIR SALTS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC AGENTS CONTAINING THESE COMPOUNDS Dr. Karl Thomae GmbH (DE) 1985-05-02 EP claimed
EP-0035161-B1 CEPHALOSPORINS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS Dr. Karl Thomae GmbH (DE) 1983-11-23 EP claimed
US-4370327-A Cephalosporins and pharmaceutical compositions BOEHRINGER INGELHEIM GMBH (DE) 1983-01-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220353-A1 Pyrrolo[2,3-d]pyrimidine compounds JAK1, CDK2, JAK3 TSHR 2761/4885LMNA 4737/4885MPO 3040/4885
US-20020068746-A1 Pyrrolo[2,3-d]pyrimidine compounds JAK1, CDK2, JAK3 TSHR 2761/4885LMNA 4737/4885MPO 3040/4885
US-20050080095-A1 administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I TRPV1, OPRL1, TRPV6 TSHR 397/4885LMNA 2257/4885MPO 2708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.